Celldex Therapeutics, Inc. — Director's Dealing 2016

Jun 9, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2016-06-08

Reporting Person: KELER TIBOR (Executive VP & CSO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-06-08	Incentive Stock Option	$4.72	A	162000	Acquired	2026-06-08	Common Stock (162000)	Direct

Footnotes

F1: 25% vest on June 8, 2017 and the remainder vest quarterly (in equal amounts)over the subsequent 12 quarters.